AB Science SA · EURONEXT:AB

AB Science SA — MSVirtual2020 (ACTRIMS-ECTRIMS) (November 2020)

16 slides from AB Science SA's conference presentation, November 2020

  1. Slide 1: Masitinib in PPMS and nSPMS multiple sclerosis: Results from phase 3 study AB07002

    Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002 P. Vermersch1, O. Hermine2 (on behalf of the AB07002 Study Group) 1 University Lille, Inserm U1172, CHU Lille, FHU Imminent, Lille, France 2 Imagine Institute,

  2. Slide 2: Rationale: The innate immune system plays a critical role in progressive forms of MS

    Rationale: The innate immune system plays a critical role in progressive forms of MS ❖ Emerging evidence indicates that Primary Progressive MS and non-active Secondary Progressive MS (nSPMS) are driven in part by activity of the innate immune system, compartmentalized within the CNS ❖ Microglia and

  3. Slide 3: Preclinical and clinical proof-of-concept

    Preclinical and clinical proof-of-concept ❖ The potential of masitinib in MS was explored using a MOG-induced experimental allergic encephalomyelitis (EAE) model, with a significant reduction in disease observed at a clinically relevant dose [1]. ❖ It is established that mast cells are necessary for

  4. Slide 4: Study AB07002 evaluated two masitinib doses in patients with PPMS and non-active SPMS

    Study AB07002 evaluated two masitinib doses in patients with PPMS and non-active SPMS ❖ Double blind, placebo controlled, 2-parallel groups ▪ Two doses tested independently, each with its own placebo control group (i.e. 4-arm study) 1. Masitinib 4.5 mg/kg/d versus its own placebo (300 patients rando

  5. Slide 5: Study AB07002 key efficacy endpoints

    Study AB07002 key efficacy endpoints ❖ Primary endpoint: Change from baseline in absolute EDSS value averaged over the 2-year study ▪ Mean of all changes from baseline in EDSS, measured at 8 time points for each pt (every 12 weeks from W12-W96) ▪ Primary analysis calculated using a GEE model (genera

  6. Slide 6: Study AB07002 key efficacy endpoints

    Study AB07002 key efficacy endpoints ❖ Sensitivity analysis of the primary endpoint ▪ Change from baseline in ordinal EDSS score averaged over the 2-year study • Gives the probability of a patient having either more improvements in EDSS or fewer worsening EDSS scores with masitinib treatment relativ

  7. Slide 7: Baseline Characteristics

    Baseline Characteristics - Masitinib 4.5 mg/kg/d ❖ Patients were enrolled at an advanced stage of disease, reflecting a difficult-to-treat population ❖ Baseline characteristics were balanced between the treatment-arms Masitinib Placebo Number randomized 200 101 ❖ Patients were enrolled at an Sex [n

  8. Slide 8: Primary Endpoint Results

    Primary Endpoint Results - Masitinib 4.5 mg/kg/d Study AB07002 met its primary analysis, demonstrating a statistically significant reduction in disability progression on EDSS (p=0.0256) ❖ Primary analysis - Mean of absolute changes from ❖ Visualization of absolute changes from baseline in baseline i

  9. Slide 9: Primary Endpoint - Sensitivity Analyses

    Primary Endpoint - Sensitivity Analyses The positive primary outcome was corroborated by numerous sensitivity analyses ❖ This included the conservative multiple imputation technique known as ‘Jump-to-Reference’ ▪ Primary analysis maintained a significant reduction in disability progression on EDSS (

  10. Slide 10: Ordinal EDSS Results

    Ordinal EDSS Results - Masitinib 4.5 mg/kg/d Sensitivity analysis based on ordinal EDSS change showed a significant, 39% increased probability of having either more improvements in EDSS or fewer worsening EDSS scores with masitinib ❖ Instead of the change in absolute EDSS, change is measured with an

  11. Slide 11: Risk of EDSS progression

    Risk of EDSS progression - Masitinib 4.5 mg/kg/d Masitinib reduced the risk of first disability progression by 42% and the risk of confirmed (3-month) disability progression by 37% ❖ Kaplan-Meier analysis - cumulative ❖ Kaplan-Meier analysis - cumulative probability of reaching first EDSS progressio

  12. Slide 12: Risk of progression to EDSS[7.0]

    Risk of progression to EDSS[7.0] - Masitinib 4.5 mg/kg/d Masitinib also significantly reduced the risk of reaching an EDSS score of 7.0, corresponding to disability severe enough that the patient is restricted to a wheelchair ❖ Kaplan-Meier analysis - cumulative ❖ Kaplan-Meier analysis - cumulative

  13. Slide 13: Safety

    Safety - Masitinib 4.5 mg/kg/d Safety was consistent with known masitinib profile with no new safety signals observed ▪ Safety dataset excluded 1 patient from ITT population because of no intake of study drug ▪ Adverse events (any grade) occurring most frequently for masitinib (MAS) compared with pl

  14. Slide 14: Masitinib 6.0 mg/kg/d - Primary Analysis

    Masitinib 6.0 mg/kg/d - Primary Analysis Results from the second parallel group, with a titrated target masitinib dose of 6.0 mg/kg/d, did not show any significant difference between treatment-arms ❖ Numerically, masitinib 6.0 mg/kg/d titration change in EDSS was comparable to the masitinib 4.5 mg/k

  15. Slide 15: Conclusions

    Conclusions Masitinib, a first-in-class tyrosine kinase inhibitor targeting the innate immune system via inhibition of mast cell and microglia/macrophage activity, may provide a new treatment option for PPMS and non-active SPMS ❖ Study AB07002 demonstrated a sustained and significant benefit for mas

  16. Slide 16: Thank you to our patients and all investigators of study AB07002

    THANK YOU TO OUR PATIENTS AND THEIR FAMILIES, & ALGERIA TO ALL INVESTIGATORS OF STUDY AB07002 GERMANY INDIA ROMANIA SOUTH AFRICA • Dr Frih Ayed • Dr Hecham • Dr Tackenberg • Dr Kumar • Dr Manescu • Dr Frost • Dr Mhrissa • Dr Schwab • Dr Radhakrishnan • Dr Deme • Dr Heckmann ARGENTINA • Dr Schoell •

AB Science — MSVirtual2020 (ACTRIMS-ECTRIMS) (November 2020) on 6ix